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Abstract Follow-up after gastrectomy for gastric cancer
has several purposes, including management of side effects
of surgery, oncological recurrence surveillance, psycholog-
ical support, and data collection for research. How follow-up
after gastrectomy, and especially recurrence surveillance, is
performed differs immensely between different Western
countries, despite guidelines from Western oncological
organizations quite unanimously advocating symptom-dri-
ven surveillance, without scheduled cross-sectional imaging,
endoscopies, or analysis of tumor markers. Given a com-
plete lack of randomized data, the available body of obser-
vational data does not support intensive routine surveillance
for recurrent disease. Moreover, studies of other cancers
have shown a negative emotional impact of routine
surveillance. There is an apparent need for randomized
controlled trials to address the issue of optimized strategies
for postgastrectomy recurrence surveillance.
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Introduction
In recent years a number of pivotal randomized controlled
trials covering different aspects of gastric cancer manage-
ment have been performed [1–6], substantially improving
the evidence platform on which treatment decisions are
made and paving the way for increased standardization of
stage-specific management. Despite these advances, there is
no international consensus on the best strategy for follow-up
after curatively intended gastrectomy for gastric cancer. A
recent publication showed that even within the relatively
homogeneous group of countries in western and central
Europe, national guidelines and practice differ immensely
regarding postgastrectomy recurrence surveillance [7].
Follow-up after gastrectomy for gastric cancer has several
components that meet different objectives. The first and most
immediate reason to follow up patients after gastrectomy is the
management of side effects caused by surgery, many of which
are associated with eating and nutrition, including malab-
sorption, weight loss, and subjective alimentary discomfort [8].
Another obvious objective of follow-up after gastrectomy is
cancer recurrence surveillance. This is a crucial aspect of fol-
low-up for most cancers, and for some, such as colorectal and
breast cancers, there is firm evidence of survival benefit from
randomized controlled trials, supporting this practice [9–11].
The design of optimal follow-up programs after gastrec-
tomy for gastric cancer is a complex task, especially balancing
the potential benefits and drawbacks of rigorous recurrence
surveillance in the context of a total lack of randomized trials
addressing this issue with specific regard to gastric cancer. The
pivotal question is whether a potential survival benefit of
rigorous surveillance outweighs the monetary costs and pos-
sible psychological burden of recurrent anxiety caused by
frequent surveillance investigations.
Follow-up components and objectives
Follow-up after surgery for gastric cancer can be catego-
rized by four main objectives: management of side effects
after surgery, cancer recurrence surveillance, psychological
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support, and data collection for treatment evaluation and
research.
Management of complications and postgastrectomy
syndrome
All types of gastrectomy for gastric cancer have short-term
and long-term effects on gastrointestinal and metabolic
function. Some of the short-term problems that patients
experience after gastrectomy are related to complications
of surgery such as leaks from anastomoses or the duodenal
stump or a number of other complications (e.g., ones of
pulmonary or cardiovascular origin). However, even in a
perfectly uneventful postoperative course, patients experi-
ence a number of side effects.
The commonest side effects, often referred to as post-
gastrectomy syndrome, are related to eating and gastroin-
testinal tract function and affect virtually all patients to
some extent in the first few months after surgery [12, 13].
These side effects include early postprandial satiety, loss of
appetite, alteration of taste, nausea/vomiting, and diarrhea.
In addition to these expected symptoms, which usually
become less apparent with time, there are a number of
more specific postgastrectomy symptom complexes, such
as dumping syndrome and afferent and efferent loop syn-
dromes, the frequency of which depend on the extent of
gastric resection and the type of reconstruction [14].
Important long-term complications following gastrec-
tomy are risks of anemia, caused by deficiencies of iron or
vitamin B12, and osteoporosis due to malabsorption of
vitamin D and calcium. Thus, most surveillance programs
include monitoring and supplementation of iron, vitamin
B12, either orally or parenterally [15], and vitamin D as
well as calcium [16].
Most patients experience weight loss after gastrectomy,
which is most pronounced in the early phase and subse-
quently usually stabilizes within the first 2 years after
surgery [17]. One of the reasons for the weight loss is
probably the discomfort related to eating described above,
but it is also to some extent explained by malabsorption
[8, 17–19].
Recurrence surveillance
The surveillance for recurrence of gastric cancer after
curative-intent gastrectomy aims at the detection of local
recurrence, either in the surgical resection line or in the
regional lymph nodes, as well as the detection of distant
metastases. There are a number of different ways that
recurrence surveillance programs can be designed with
different investigational modalities such as cross-sectional
imaging with computerized tomography (CT), with or
without positron emission tomography, magnetic
resonance imaging, ultrasonography, endoscopy, or tumor
markers (TM) in blood samples. However, the main line of
division is between surveillance programs that actively
seek asymptomatic recurrent disease with regular exami-
nation with combinations of imaging, endoscopy, and
tumor markers and those follow-up programs that offer
clinical assessment only at office visits, with targeted
investigation only at the occurrence of symptoms or other
reasons to suspect recurrence [8].
Psychological support
A crucial aspect of follow-up after gastric cancer surgery is
to provide psychological support and reassurance to the
patient and the surrounding family. This is a complex task
given the severity of the disease, with a very high recur-
rence risk and the extremely poor prognosis in the event of
recurrence [20–22], with palliative therapy being the only
option in the vast majority of patients in whom recurrence
is diagnosed. An important question to address in this
context is which of the two main surveillance options,
regular scheduled investigation aiming at detection of a
presymptomatic phase of cancer recurrence, or symptom-
driven investigation only, is most beneficial for patients
from a specific psychological and broader quality-of-life
perspective.
Data collection for treatment evaluation
and research
The systematic gathering and evaluation of data on patients
with gastric cancer is of obvious and major importance.
Structured follow-up programs after treatment of gastric
cancer, not only in the context of prospective clinical trials
but also in the daily clinical practice at every hospital and
involving every patient in whom gastric cancer has been
diagnosed, are important to meet this objective. In many
Western countries, such as the UK, Sweden, Denmark,
Germany, and the Netherlands, there are national registries
or mandatory national audits, with registration of at least
all patients undergoing surgery, but in some countries also
including nonsurgically treated patients with gastric cancer
[23, 24].
Oncological recurrence surveillance in different
Western countries
In a recently published description of clinical pathways for
gastric and esophageal adenocarcinoma in ten European
countries, it was clearly shown that the pathways used for
oncological recurrence surveillance differed immensely,
even between these otherwise quite similar western and
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central European countries [7]. Some countries included in
the survey such as Denmark, the Netherlands, Ireland,
Poland, Sweden, and the UK based their oncological
surveillance mainly on clinical assessment at regular office
visits, without scheduled cross-sectional imaging or anal-
ysis of tumor markers, performing these or other sophisti-
cated investigations only in the event of clinical suspicion
of recurrence. Other countries, including France, Germany,
Italy, and Spain, had more elaborate programs with actual
surveillance for nonsymptomatic recurrence, including
scheduled regular cross-sectional imaging with CT and the
examination of tumor markers in blood samples. In Poland
the clinical evaluations at office visits were supplemented
with ultrasonography, and in some of these countries
endoscopy was also used for surveillance of local recur-
rence or new primary tumors in patients with a remnant
stomach [7].
Likewise, the practice of recurrence surveillance after
gastrectomy for gastric cancer is likely to differ consider-
ably in other Western countries and regions (e.g., in North
America, Australia, and New Zealand). However, to my
knowledge there are no publications available documenting
the postgastrectomy practices in these countries and
regions.
Western guidelines and consensus documents
There are a number of guidelines and consensus documents
issued by national and international professional organi-
zations addressing the issue of postgastrectomy follow-up
for gastric cancer patients. In some contrast to the differ-
ences discussed earlier regarding follow-up practices in
different Western countries, Western guidelines from
health-profession organizations are quite unanimous in
advocating follow-up with symptom-driven recurrence
investigations only. These guidelines include the joint ones
from the European Society for Medical Oncology, the
European Society of Surgical Oncology, and the European
Society of Radiotherapy and Oncology from 2013 [25], the
joint ones from the Association of Upper Gastrointestinal
Surgeons of Great Britain and Ireland, the British Associ-
ation of Gastroenterology, and the British Association of
Surgical Oncology from 2011 [26], and the guidelines from
the US National Comprehensive Cancer Network from
2013 [27] In a consensus document, based on the Charter
Scaligero Consensus Conference in Verona in 2013, 48
gastric cancer experts from around the world concluded
that follow-up after gastrectomy for cancer should be tai-
lored to the stage of the disease, mainly based on cross-
sectional imaging, and should be discontinued after 5 years
[28]. It is notable that this is the only published major
consensus guideline, with a predominant influence of
Western experts, advocating regular cross-sectional
imaging.
Is there evidence of an oncological benefit
of postgastrectomy surveillance?
For several other cancers, among them notably colorectal
and breast cancer, there are a number of randomized
clinical trials that clearly show that intensive surveillance
for asymptomatic recurrence increases overall survival
compared with symptom-driven recurrence investigation
only [9–11]. Characteristic for these cancers, however, and
in some contrast to the situation regarding gastric cancer,
there is a proven strong survival benefit from intense
treatment of recurrent distant metastatic disease, including
the quite extensive use of therapy guided by molecular
profiling and the proven benefit of liver and lung resections
for the removal of metastases [9]. Several series have been
published reporting long-term survival in selected patients
after resection of metachronous gastric cancer liver
metastases. However, these series represent highly selected
patients, and there are no data from randomized trials. For
gastric cancer, there is clear evidence from randomized
clinical trials showing a survival benefit of palliative
chemotherapy compared with best supportive care only
[29–31], although these effects are modest compared with
those for the above-mentioned cancer forms. Hence, given
that there is a survival benefit from palliative chemother-
apy, there is a reasonable rationale for active surveillance
for recurrence assuming that early detection may facilitate
chemotherapy as a higher proportion of patients are likely
to have a high performance status and be able to tolerate
treatment, thus possibly enhancing treatment results. On
the other hand, there is likewise a risk that more patients
may be treated with more side effects and poorer quality of
life, without a significant advantage in terms of increased
survival. Let us scrutinize the available evidence.
Unfortunately, there are no published or ongoing ran-
domized trials comparing intensive surveillance for non-
symptomatic recurrence with symptom-driven follow-up
for gastric cancer. Thus, all the available evidence
addressing this important clinical question is observational
in nature. See Table 1 for an overview of studies
addressing survival benefit of recurrence surveillance.
In 2012 Cardoso et al. [22] published a systematic
review summarizing the studies available at that time. All
five studies selected to relevantly address the issue were
retrospective observational studies, and the authors’ con-
clusion was that there was no evidence to suggest that
surveillance after gastrectomy for gastric cancer had any
survival benefit. Three of the studies [32–34] simply
compared patients with symptomatic recurrences with
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those with asymptomatic recurrences. They all showed
significantly increased postrecurrence survival in patients
with asymptomatically detected recurrences, a finding
which may very well be entirely explained by lead-time
bias. The only one of these three studies that reported
overall survival did not observe any difference between
symptomatically and asymptomatically detected recur-
rences [34]. The study by Tan and So [35] compared an
intensive follow-up regimen that included twice annual
clinical examination, CT, and tumor marker assessment
with a regimen with maximal once annual investigation.
They found that the intensive surveillance significantly
shortened the time to detection of recurrence from a mean
of 19.2 months in the low-intensity surveillance group to
11.5 months in the intensive surveillance group
(P = 0.02), while not significantly affecting overall sur-
vival after surgery.
In recent years a few more observational studies
addressing the issue of the oncological benefit of intensive
surveillance have been published [36–40], Bilici et al.
[37] published a retrospective series in 2013, where they,
like most previous authors, compared symptomatic
recurrences with asymptomatic recurrences and showed
significantly longer overall survival among patients with
asymptomatic recurrence, in addition to the expected
longer postrecurrence survival. There was a slightly
longer disease-free survival, reflecting the time to detec-
tion of recurrence, in the asymptomatic group. Bilici et al.
suggest that these findings may be explained by symp-
tomatic recurrence perhaps being a marker of biological
aggressiveness of the cancer. Likewise, Lee et al. [41]
found that both postrecurrence survival and overall
survival were longer in patients with asymptomatic
recurrences, whereas the time to recurrence did not differ,
indicating that the increased survival in the asymptomatic
group may indeed be due to selection of patients with less
aggressive disease rather than to an intervention benefit of
surveillance [41].
Recent studies addressing surveillance regimens of dif-
ferent intensity have failed to show any difference in
overall survival between these [39, 40]. In a Canadian
cohort study based on prospectively collected data, Peixoto
et al. [39] studied patients operated on for gastroesophageal
cancer with curative intent and followed up with regimens
of different diagnostic intensity. They concluded that after
multivariably adjusted analyses, there was no difference in
overall survival in a comparison of symptom-driven fol-
low-up with more vigorous surveillance that included
regular imaging. Lastly, Park et al. [40], in a study from
Korea, compared surveillance programs with CT exami-
nations of different frequency after gastrectomy for gastric
cancer, ranging from CT every 3 months to every
6–12 months, but did observe any difference in overall
survival between these groups.
The role of endoscopy in surveillance for cancer
recurrence after R0 gastrectomy is very limited [8, 38, 43].
On the other hand, endoscopy does have a significant role
in searching for second primary gastric cancers after non-
total gastrectomy [42–44]. Patients who undergo resection
for gastric cancer have a significantly increased risk of new
primary gastric cancers, and the prognosis in these patients
is excellent if detection is early, but poor if a second pri-
mary tumor is detected at a later stage (T2 or higher)
[44–46].
Table 1 Observational studies addressing gastric cancer recurrence surveillance after gastrectomy
Authors Publication year Variables compared Main outcomes Results
Bohner et al. [33] 2000 Symptomatic vs asymptomatic recurrence PRS Longer PRS in asymptomatic
group
Kodera et al. [34] 2003 Symptomatic vs asymptomatic recurrence PRS, OS Longer PRS in asymptomatic
group. No difference in OS
Bennett et al. [32] 2005 Symptomatic vs asymptomatic recurrence PRS Longer PRS in asymptomatic
group
Tan and So [35] 2007 Intensive vs less intensive surveillance Time to recurrence Shorter time to recurrence for
intensive surveillance group, no
difference in OS
Eom et al. [36] 2011 Recurrence detected by surveillance vs by
symptoms
OS No difference
Bilici et al. [37] 2013 Symptomatic vs asymptomatic recurrence DFS, PRS, OS Longer DFS, PRS, and OS in
asymptomatic group
Lee et al. [38] 2014 Symptomatic vs asymptomatic recurrence DFS, PRS, OS Longer DFS, PRS, and OS in
asymptomatic group
Peixoto et al. [39] 2014 Intensive vs symptom-driven surveillance OS No difference
Park et al. [40] 2016 Intensive vs less intensive surveillance OS No difference




There are no published studies regarding the impact of
gastric cancer recurrence surveillance with regard to its
psychological effects or effects on health-related quality of
life. There is, however, a large body of literature con-
cerning the psychological impact of recurrence surveil-
lance in other cancer forms, especially breast, prostate, and
colorectal cancer [47–49]. It is evident from these studies
that many patients experience severe anxiety related to
testing for recurrence or disease progression.
An important difference between gastric cancer and
breast, prostate, and colorectal cancers is that the prognosis,
if a recurrence is diagnosed, is relatively good compared
with the generally very short life expectancy of patients with
recurrent gastric cancer. Adult aggressive lymphoma is a
malignant disease with a high degree of prognostic resem-
blance to gastric cancer. Thompson et al. [50] reported on
the psychological impact of recurrence surveillance CT
scans after curative-intent treatment of patients with this
disease. Using mixed qualitative interview and quantitative
techniques, they observed that patients experienced signifi-
cant anxiety related to the surveillance CT scans, and they
concluded that ‘‘it is possible that the harm of routine
surveillance scans for survivors of aggressive lymphoma
may outweigh the value, given the lack of randomized data
on the effectiveness of the current practice standards, false-
positive findings, high cost, radiation exposure, and negative
emotional impact on patients.’’
Conclusions
Follow-up after gastrectomy for gastric cancer has several
purposes, including management of side effects after sur-
gery, oncological recurrence surveillance, psychological
support, and data collection for research. Despite the fact
that guidelines from Western health professional organi-
zations are quite unanimous in recommending symptom-
driven recurrence surveillance only, practice in Western
countries differs, and often includes intensive surveillance
with CT and analysis of tumor markers. There are no data
available from randomized controlled trials addressing how
recurrence surveillance after gastrectomy for gastric cancer
should best be performed. However, the available obser-
vational evidence does not support routine surveillance for
asymptomatic cancer recurrence. In addition, there is some
evidence from other cancers indicating that intensive rou-
tine surveillance may have a negative emotional impact on
patients. In conclusion, there is a strong need for ran-
domized clinical trials addressing postgastrectomy
surveillance intensity with regard to survival, psychologi-
cal impact, and health-related quality of life.
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